Analyst Terence Flynn from Morgan Stanley maintained a Hold rating on Biogen (BIIB – Research Report) and keeping the price target at ...

Wolfe Research analyst Alexandria Hammond initiated coverage of Biogen (BIIB) with a Peer Perform rating. With a legacy portfolio that ...

A European regulatory committee now recommends approval of the Alzheimer's treatment lecanemab a few months after rejecting ...

Biogen’s stock rose 1% Thursday, after Europe’s pharmaceutical regulator issued a positive opinion on the Alzheimer’s disease ...

A slow launch for Alzheimer's medicine Leqembi, a lackluster pipeline and a challenging drug launch environment are just a ...

A European regulatory committee now recommends approval of the Alzheimer’s treatment lecanemab a few months after rejecting ...

Shares of Biogen Inc. BIIB slid 1.48% to $165.79 Wednesday, on what proved to be an all-around favorable trading session for ...

A key regulatory committee sided against the drug this summer. But an appeal from Eisai appears to have worked, teeing Leqembi up for authorization in a major market.

Shares of Hims & Hers Health slumped 15% on Thursday after Amazon.com launched a rival service that offers upfront pricing ...

The institutional investor owned 2,537 shares of the biotechnology company’s stock after selling 475 shares during the quarter. QRG Capital Management Inc.’s holdings in Biogen were worth $ ...

DelveInsight's 'Multiple Sclerosis Pipeline Insight 2024' report provides comprehensive global coverage of pipeline multiple ...

Investing.com -- KeyBanc Capital Markets downgraded Papa John’s International (PZZA) from Overweight to Sector Weight on Thursday, citing a prolonged path to recovery for the pizza chain.